APA

Appenzeller S., Gesierich A., Thiem A., Hufnagel A., Jessen C., Kneitz H., Regensburger M., Schmidt C., Zirkenbach V., Bischler T., Schilling B., Siedel C., Goebeler M., Houben R., Schrama D., Gehrig A., Rost S., Maurus K., Bargou R., Rosenwald A., Schartl M., Goebeler M. & Meierjohann S. (20191211). The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas. : Cancer.

Chicago

Appenzeller Silke, Gesierich Anja, Thiem Alexander, Hufnagel Anita, Jessen Christina, Kneitz Hermann, Regensburger Martina, Schmidt Cornelia, Zirkenbach Vanessa, Bischler Thorsten, Schilling Bastian, Siedel Claudia, Goebeler Maria-Elisabeth, Houben Roland, Schrama David, Gehrig Andrea, Rost Simone, Maurus Katja, Bargou Ralf, Rosenwald Andreas, Schartl Manfred, Goebeler Matthias and Meierjohann Svenja. 20191211. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas. : Cancer.

Harvard

Appenzeller S., Gesierich A., Thiem A., Hufnagel A., Jessen C., Kneitz H., Regensburger M., Schmidt C., Zirkenbach V., Bischler T., Schilling B., Siedel C., Goebeler M., Houben R., Schrama D., Gehrig A., Rost S., Maurus K., Bargou R., Rosenwald A., Schartl M., Goebeler M. and Meierjohann S. (20191211). The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas. : Cancer.

MLA

Appenzeller Silke, Gesierich Anja, Thiem Alexander, Hufnagel Anita, Jessen Christina, Kneitz Hermann, Regensburger Martina, Schmidt Cornelia, Zirkenbach Vanessa, Bischler Thorsten, Schilling Bastian, Siedel Claudia, Goebeler Maria-Elisabeth, Houben Roland, Schrama David, Gehrig Andrea, Rost Simone, Maurus Katja, Bargou Ralf, Rosenwald Andreas, Schartl Manfred, Goebeler Matthias and Meierjohann Svenja. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas. : Cancer. 20191211.